Zacks Research Analysts Decrease Earnings Estimates for AGIO

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Research analysts at Zacks Research decreased their Q2 2028 EPS estimates for shares of Agios Pharmaceuticals in a research report issued on Friday, June 26th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings per share of ($1.21) for the quarter, down from their previous estimate of ($1.07). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.28) per share.

Other equities research analysts also recently issued reports about the stock. JPMorgan Chase & Co. reduced their price objective on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a research report on Thursday, June 11th. Bank of America reduced their target price on Agios Pharmaceuticals from $41.00 to $40.00 and set a “buy” rating for the company in a report on Friday, May 29th. HC Wainwright dropped their price target on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Citigroup boosted their price objective on Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Finally, Wall Street Zen upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. Six research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $40.89.

Agios Pharmaceuticals Stock Down 0.1%

AGIO stock opened at $37.08 on Thursday. The firm has a market capitalization of $2.21 billion, a PE ratio of -5.11 and a beta of 0.54. The stock’s 50 day moving average is $29.75 and its 200-day moving average is $29.18. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.12. The business had revenue of $20.75 million during the quarter, compared to the consensus estimate of $13.30 million. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The company’s revenue for the quarter was up 137.7% compared to the same quarter last year.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. purchased a new stake in Agios Pharmaceuticals in the fourth quarter worth $25,000. Assetmark Inc. lifted its position in shares of Agios Pharmaceuticals by 37.9% during the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 362 shares during the last quarter. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals during the 1st quarter worth $40,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Agios Pharmaceuticals during the 4th quarter worth $49,000. Finally, Eurizon Capital SGR S.p.A. purchased a new stake in Agios Pharmaceuticals in the 4th quarter worth about $72,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.